

**Anti-PKR Antibody**  
**Rabbit polyclonal antibody to PKR**  
**Catalog # AP60453****Specification**

---

**Anti-PKR Antibody - Product Information**

Application	WB
Primary Accession	<a href="#">P19525</a>
Other Accession	<a href="#">Q03963</a>
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	62094

**Anti-PKR Antibody - Additional Information****Gene ID** 5610**Other Names**

PKR; PRKR; Interferon-induced, double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2; eIF-2A protein kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein kinase; Protein kinase RNA-activated; PKR; Tyrosine-protein kinase EIF2AK2; p68 kinase

**Target/Specificity**

Recognizes endogenous levels of PKR protein.

**Dilution**

WB~~WB (1/500 - 1/1000), IH (1/100 - 1/200)

**Format**

Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide.

**Storage**

Store at -20 °C.Stable for 12 months from date of receipt

**Anti-PKR Antibody - Protein Information****Name** EIF2AK2**Synonyms** PKR, PRKR**Function**

IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection (PubMed:<a href="http://www.uniprot.org/citations/18835251" target="\_blank">18835251</a>, PubMed:<a

[19189853](http://www.uniprot.org/citations/19189853), PubMed: [19507191](http://www.uniprot.org/citations/19507191), PubMed: [21072047](http://www.uniprot.org/citations/21072047), PubMed: [21123651](http://www.uniprot.org/citations/21123651), PubMed: [22381929](http://www.uniprot.org/citations/22381929), PubMed: [22948139](http://www.uniprot.org/citations/22948139), PubMed: [23229543](http://www.uniprot.org/citations/23229543)). Inhibits viral replication via the integrated stress response (ISR): EIF2S1/eIF-2- alpha phosphorylation in response to viral infection converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting to a shutdown of cellular and viral protein synthesis, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activator ATF4 (PubMed: [19189853](http://www.uniprot.org/citations/19189853), PubMed: [21123651](http://www.uniprot.org/citations/21123651), PubMed: [22948139](http://www.uniprot.org/citations/22948139), PubMed: [23229543](http://www.uniprot.org/citations/23229543)). Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1) (PubMed: [11836380](http://www.uniprot.org/citations/11836380), PubMed: [19189853](http://www.uniprot.org/citations/19189853), PubMed: [19840259](http://www.uniprot.org/citations/19840259), PubMed: [20171114](http://www.uniprot.org/citations/20171114), PubMed: [21710204](http://www.uniprot.org/citations/21710204), PubMed: [23115276](http://www.uniprot.org/citations/23115276), PubMed: [23399035](http://www.uniprot.org/citations/23399035)). Also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation: phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed: [11836380](http://www.uniprot.org/citations/11836380), PubMed: [19229320](http://www.uniprot.org/citations/19229320), PubMed: [22214662](http://www.uniprot.org/citations/22214662)). In addition to serine/threonine- protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteasomal degradation (PubMed: [20395957](http://www.uniprot.org/citations/20395957)). Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding pro-inflammatory cytokines and IFNs (PubMed: [22948139](http://www.uniprot.org/citations/22948139), PubMed: [23084476](http://www.uniprot.org/citations/23084476), PubMed: [23372823](http://www.uniprot.org/citations/23372823)). Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6 (PubMed: [10848580](http://www.uniprot.org/citations/10848580), PubMed: [15121867](http://www.uniprot.org/citations/15121867), PubMed: [15229216](http://www.uniprot.org/citations/15229216)). Can act as both a positive and negative regulator of the insulin signaling pathway (ISP) (PubMed: [20685959](http://www.uniprot.org/citations/20685959)). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2) (PubMed: [20685959](http://www.uniprot.org/citations/20685959)). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes (PubMed: [22801494](http://www.uniprot.org/citations/22801494)). Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin (By similarity).

## Cellular Location

Cytoplasm. Nucleus. Cytoplasm, perinuclear region. Note=Nuclear localization is elevated in acute leukemia, myelodysplastic syndrome (MDS), melanoma, breast, colon, prostate and lung cancer patient samples or cell lines as well as neurocytes from advanced Creutzfeldt- Jakob disease patients.

#### Tissue Location


Highly expressed in thymus, spleen and bone marrow compared to non-hematopoietic tissues such as small intestine, liver, or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer disease (AD) brain. Elevated levels seen in breast and colon carcinomas, and which correlates with tumor progression and invasiveness or risk of progression.

#### Anti-PKR Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### Anti-PKR Antibody - Images



Western blot analysis of PKR expression in HCC827 (A), SGC7901 (B), A375 (C), MCF7 (D) whole cell lysates.



Immunohistochemical analysis of PKR staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

#### **Anti-PKR Antibody - Background**

KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human PKR. The exact sequence is proprietary.